← All indications
Carcinoma, Adenoid Cystic
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
Drugs by status
Phase 2 trials (42)
- lutetium (177Lu) vipivotide tetraxetan
- 2-fluoropropionyl-labeled pegylated dimeric rgd peptide
- Ga 68 PSMA-11
- abemaciclib
- axitinib
- avelumab
- bms-906024
- dovitinib
- doxorubicin
- imatinib
- lapatinib
- nivolumab
- pembrolizumab
- lenvatinib
- msk-2206
- regorafenib
- pemetrexed
- ipilimumab
- sunitinib
- carboplatin
- bevacizumab
- cetuximab
- talimogene laherparepvec
- dasatinib
- everolimus
- bortezomib
- vorinostat
- gefitinib
- enfortumab vedotin
- erlotinib
- +12 more
Phase 1 trials (27)
Other trials (4)
Organizations
Organization Involved with Phase 2 Indications (39)
- Eisai
- Millennium Pharmaceuticals
- Merck
- Merck KGaA
- Pfizer
- Novartis
- Bayer
- National Cancer Institute (NCI)
- University of Pittsburgh
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- McMaster University
- Radboud University
- Rutgers University
- Seoul National University
- Southwest Oncology Group
- Stanford University
- University of Heidelberg
- University of Iowa
- University of Milan
- University of Toronto
- Wayne State University
- University of Virginia
- Fudan University
- University of Chicago
- Jiao Tong University
- Institut Gustave Roussy
- European Organisation for Research and Treatment of Cancer
- University of Texas at Houston
- +9 more
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (2)